IN2014DN11181A - - Google Patents

Info

Publication number
IN2014DN11181A
IN2014DN11181A IN11181DEN2014A IN2014DN11181A IN 2014DN11181 A IN2014DN11181 A IN 2014DN11181A IN 11181DEN2014 A IN11181DEN2014 A IN 11181DEN2014A IN 2014DN11181 A IN2014DN11181 A IN 2014DN11181A
Authority
IN
India
Prior art keywords
apc
treat
individual
methods
effective amount
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher John Jackson
Meilang Xue
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902874A external-priority patent/AU2012902874A0/en
Application filed by Univ Sydney filed Critical Univ Sydney
Publication of IN2014DN11181A publication Critical patent/IN2014DN11181A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN11181DEN2014 2012-07-04 2013-07-04 IN2014DN11181A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (1)

Publication Number Publication Date
IN2014DN11181A true IN2014DN11181A (pt) 2015-10-02

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11181DEN2014 IN2014DN11181A (pt) 2012-07-04 2013-07-04

Country Status (13)

Country Link
US (3) US20150150954A1 (pt)
EP (1) EP2869833B1 (pt)
JP (1) JP6273272B2 (pt)
KR (1) KR102068010B1 (pt)
CN (1) CN104394883B (pt)
AU (1) AU2013286812B2 (pt)
BR (1) BR112015000051A2 (pt)
CA (1) CA2877745C (pt)
ES (1) ES2676422T3 (pt)
HK (1) HK1204573A1 (pt)
IN (1) IN2014DN11181A (pt)
RU (1) RU2662564C2 (pt)
WO (1) WO2014005183A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
CA2946028C (en) * 2014-04-16 2022-10-11 Zz Biotech Llc Treatment of abnormal cutaneous scarring
PL3131572T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
WO2018068759A1 (zh) 2016-10-14 2018-04-19 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
US20210268062A1 (en) * 2018-06-28 2021-09-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
EP3902605A4 (en) * 2018-12-26 2022-09-28 Direct Biologics LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN AND HAIR DISEASES
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
JPH03501921A (ja) 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
EA002149B1 (ru) 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
AU2001238034A1 (en) 2000-02-04 2001-08-14 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
WO2001072328A2 (en) * 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
JP4071105B2 (ja) 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
ATE550073T1 (de) * 2001-06-13 2012-04-15 Univ Sydney Protein c für die wundheilung
WO2004041296A2 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
DK1477166T3 (da) 2003-04-28 2006-12-11 Biofrontera Bioscience Gmbh Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US7498305B2 (en) 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
EP1841442A4 (en) * 2005-01-07 2009-12-09 Northern Sydney And Central Co TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
ZA200800251B (en) 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
WO2007019345A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
MX2011010401A (es) * 2009-04-01 2012-01-20 Rappaport Family Inst Res In The Medical Sciences Un metodo para regular la proliferacion y deferenciacion de queratinocitos.
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
CA2946028C (en) 2014-04-16 2022-10-11 Zz Biotech Llc Treatment of abnormal cutaneous scarring
PL3131572T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
US20210268062A1 (en) * 2018-06-28 2021-09-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Also Published As

Publication number Publication date
RU2015103510A (ru) 2016-08-27
US20200276281A1 (en) 2020-09-03
JP2015521632A (ja) 2015-07-30
WO2014005183A1 (en) 2014-01-09
US20150150954A1 (en) 2015-06-04
EP2869833A4 (en) 2015-11-18
CN104394883A (zh) 2015-03-04
JP6273272B2 (ja) 2018-01-31
KR102068010B1 (ko) 2020-01-20
AU2013286812A1 (en) 2015-01-22
CN104394883B (zh) 2017-05-31
KR20150036351A (ko) 2015-04-07
US20170080062A1 (en) 2017-03-23
EP2869833A1 (en) 2015-05-13
AU2013286812B2 (en) 2017-04-20
CA2877745C (en) 2021-11-30
BR112015000051A2 (pt) 2017-06-27
US11617785B2 (en) 2023-04-04
EP2869833B1 (en) 2018-04-04
RU2662564C2 (ru) 2018-07-26
ES2676422T3 (es) 2018-07-19
HK1204573A1 (en) 2015-11-27
CA2877745A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
PH12018500452A1 (en) Novel modulators and methods of use
IN2014DN11181A (pt)
PH12015500525A1 (en) Formulations of enzalutamide
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
BR112014017799A8 (pt) Compostos inibidores de metaloenzima
MY165759A (en) Pull-on diaper
UA110813C2 (uk) Лікування ліподистрофії
IN2014DN00288A (pt)
IN2014DN00286A (pt)
IN2014MN00093A (pt)
UA116090C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
IN2014MN01378A (pt)
LT2890793T (lt) Lakių dienų gamyba, fermentiniu būdu (ec 4.2.1.127) dehidratuojant lengvuosius alkenolius
IN2014DN08481A (pt)
UY34652A (es) Anticuerpos humanos frente a toxinas de clostridium difficile
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
MY167652A (en) Disposable diaper
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
GEP201706626B (en) Synthesis of (s)-nifuratel
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
PH12014502065A1 (en) Vesicular formulations